Biotech

Writing the book, literally, on bioelectronic medicine

By GREGORY ZELLER // The pioneering work of several key researchers has made Long Island a focal point in the emerging science of bioelectronic medicine – their combined knowledge and achievements could fill a book. And it has. Fresh off the Cold Spring Harbor Laboratory Press comes “Bioelectronic Medicine: A Subject Collection From Cold Spring Harbor Perspectives in Medicine,” which belies that awkward academic title with a sharp and exciting focus: groundbreaking progress in bioelectronics,…


With pilot run ending, top marks for LI Bioscience Hub

By GREGORY ZELLER // The Long Island Bioscience Hub is making the grade, according to a report card prepared by independent evaluators. Since launching in 2015, the LIBH – a National Institutes of Health effort uniting Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory and Northwell Health’s Feinstein Institute for Medical Research – has trained hundreds of innovators, helped fund dozens of technology-development projects and assisted the formation of numerous startup companies and…


For secure signatures, DNA is mightier than the sword

By GREGORY ZELLER // One of Long Island’s busiest biotechs has (literally) inked an exclusive security deal with a leading global penmaker. Stony Brook-based Applied DNA Sciences this week announced a five-year agreement with German manufacturer Montblanc-Simplo GMHB, master of not only “luxury writing instruments,” according to the Hamburg-based company’s website, but a wide range of watches, jewelry, eyewear, leather goods and other personal (and personalized) products. Pens, however, will be the focus of the…


With synthetic opioids lurking, DNA detector scores

By GREGORY ZELLER // With synthetic opioids increasingly implicated in the alarming number of drug-overdose deaths plaguing the nation, a stalwart Long Island biotech’s DNA-based tracking technology has received a major endorsement. The peer-reviewed scientific journal PLOS ONE has published a paper by Stony Brook-based Applied DNA Sciences on the molecular tagging of pharmaceuticals – a next-gen supply-chain authenticator that Applied DNA considers unforgeable, inescapable and particularly useful in a world where counterfeit drugs are…


Feinstein stimulates talk of an arthritis breakthrough

By GREGORY ZELLER // An encouraging new study out of the Feinstein Institute for Medical Research says noninvasive bioelectronic stimulation – administered through the outer ear – can effectively reduce symptoms of rheumatoid arthritis. The potentially quantum leap for the treatment of RA and other inflammatory diseases was reported Tuesday in Bioelectronic Medicine, an open-access journal aggregating articles and data from across a dozen-plus basic and clinical disciplines, including biochemistry, neuroscience, bioengineering, artificial intelligence and…


Honey, I shrunk the shrew (and maybe your kidney)

By GREGORY ZELLER // Cutting-edge evolutionary science meets a Rick Moranis movie in an innovative international study of a surprisingly shrinkable furball. Freshly supported by a three-year grant from the international Human Frontier Science Program, Liliana Dávalos, a professor in the Department of Ecology and Evolution in Stony Brook University’s College of Arts and Sciences, will dive even deeper into the world of the shrew – a remarkable, mole-like mammal known to shrink its mass, including…


New licensing deal adds fresh buzz to joint venture

By GREGORY ZELLER // A partnership between a Stony Brook biotech and a Canadian pharmaceutical-solutions provider is growing like a weed. Less than a year since introducing the world’s first DNA-based cannabis-tagging system and just five months since they upgraded the system to accommodate large-scale growers, Applied DNA Sciences and Canadian/Panamanian cohort TheraCann International Benchmark Corp. have inked an exclusive licensing deal. The skinny: a long-term licensing agreement pairing Applied DNA’s proprietary CertainT supply chain…


Globetrotting Applied DNA has it made in Taiwan

By GREGORY ZELLER // Look out, Asia – here comes Applied DNA Sciences. Picking up where it left off at the end of a hyper-busy 2018 – in which it expanded its DNA-based supply-chain-authentication portfolio to include pharmaceuticals manufacturing in Pennsylvania, legalized marijuana distribution in Canada and a host of other supply chains in domestic and international markets – the Stony Brook-based biotech is sending its product-traceability solutions deep into to “the heart of Asia’s…


Applied DNA makes its bed, U.S. retailers to jump in

By GREGORY ZELLER // Inspired by Applied DNA Sciences’ molecular-tagging technology, a global textiles manufacturer is climbing into bed with the “circular economy.” Actually, India-based GHCL Ltd. has already bedded the so-called circular economy (referencing a regenerative system in which waste and emissions are minimized by narrowing energy and material loops, mostly through recycling and manufacturing upgrades). The manufacturer is knee-deep in recycled materials, including entire linen lines formulated from recycled polyethylene terephthalate (you may…


At LineaRX, putting the horsepower behind the CAR T

By GREGORY ZELLER // Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform. In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer. The tech comes from LineaRx Inc., a wholly owned subsidiary that officially spun off from Stony Brook-based Applied DNA Sciences in September. Noting…


International partners looking to grow pot-tagging biz

By GREGORY ZELLER // Two months after introducing the world’s first DNA-based cannabis-tagging system, a Stony Brook biotech and its Canadian partner are looking to increase their stash of legal-marijuana growers. Supply-chain security and product-authentication specialist Applied DNA Sciences and Canadian pharmaceutical-solutions provider TheraCann International Benchmark Corp. this week announced an upgraded system designed to accommodate different sizes and type of growers – particularly larger-volume cannabis and hemp growers. The next generation of TheraCann International’s…


With new spinoff, biotech goes all-in on DNA sales

By GREGORY ZELLER // A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. Stony Brook-based Applied DNA Sciences on Tuesday announced the formation of LineaRx Inc., a wholly owned subsidiary that will concentrate on commercializing the parent company’s extensive experience in the design, manufacture and chemical modification of DNA by large-scale polymerase chain reaction – big news for scientists working…


For lupus patients, a possible ACE in the hole

By GREGORY ZELLER // A common pharmaceutical treatment for hypertension could be the key to preserving brain function in lupus patients. So says data published this month in the Journal of Experimental Medicine by an international team of scientists led by the redoubtable Betty Diamond, head of the Feinstein Institute for Medical Research’s Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases and a professor of molecular medicine at the Donald and Barbara Zucker School of Medicine…


For Applied DNA, ETCH Biotrace may be a pot of gold

By GREGORY ZELLER // Just six months after announcing a partnership to develop a new molecular-tracking system, a Long Island biotech and a Canadian medical-marijuana supplier are launching the world’s first cannabis tagging system. Stony Brook-based supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist Applied DNA Sciences and Calgary-based pharmaceutical-solutions provider TheraCann International Benchmark Corp. on Tuesday announced the launch of ETCH Biotrace, which leverages Applied DNA’s CertainT platform to tag, test and track cannabis plants “in…


Nerve-stim startup Sanguistat shuffles its deck

By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized global leaders in the burgeoning field of biolelectronic medicine. Sanguistat Inc., a 2016 clinical-stage medical-device startup, has named Feinstein Institute President and CEO Kevin Tracey as chairman of its Scientific Advisory Board, a role that will leverage the pioneer’s decades of groundbreaking bioelectronics research. The…